Raymond James: Ra Pharmaceuticals (RARX) has $18 Target Has New Rating.

June 29, 2018 - By Lena Young

What Price Target Has Raymond James Given Ra Pharmaceuticals (RARX)

Stock research analysts at Raymond James gave Outperform rating and has target of $18 on RARX’s shares. On Thursday, 28 June a coverage has initiated with Ra Pharmaceuticals (RARX)‘s stock.

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Ratings Coverage

A total of 3 analysts rate Ra Pharmaceuticals (RARX) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (RARX) has 4 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Thursday, January 18 Credit Suisse reinitiated Ra Pharmaceuticals, Inc. (NASDAQ:RARX) with “Buy” rating. On Thursday, March 15 the stock of Ra Pharmaceuticals, Inc. (NASDAQ:RARX) earned “Outperform” rating by BMO Capital Markets. The stock rating was maintained by Credit Suisse with “Outperform” on Tuesday, February 13.

The stock increased 1.11% or $0.1103 during the last trading session, touching $10.0103.Ra Pharmaceuticals, Inc. has volume of 80,986 shares. Since June 29, 2017 RARX has declined 75.06% and is downtrending. The stock underperformed the S&P 500 by 87.63%.

On August, 8 WallStreet awaited Ra Pharmaceuticals, Inc. (NASDAQ:RARX)’s earnings report, according to Zacks. The earnings per share diference is $0.03 or 5.36 % up from last years number. Previous year: $-0.56; Analysts forcast: $-0.53. Wall Street now forecasts -13.11 % EPS growth despite Ra Pharmaceuticals, Inc. last quarter’s EPS of $-0.61.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States.The firm is worth $323.20 million. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.Currently it has negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria ; and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN).

A couple more Ra Pharmaceuticals, Inc. (NASDAQ:RARX) news were posted by: Businesswire.com which released on May 31, 2018 “Ra Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference”, also Businesswire.com on June 05, 2018 posted “Congress of the European Academy of Neurology”, the next Businesswire.com is “Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC …” on June 15, 2018. Benzinga.com has article titled “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …”.

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.